1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025

Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025

  • July 2020
  • 222 pages
  • ID: 5932046
  • Format: PDF
  • Kuick Research

Summary

Table of Contents

"Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025" Report Highlights:

• Bangladesh Pharmaceutical Market Opportunity: More Than US$ 6 Billion by 2025
• Share Of Local Pharmaceutical Companies: >90%
• Share of Generics Drugs in Pharmaceutical Market: >75%
• Leading Drugs Market Insight by Availability, Dosage & Price Analysis
• Number of Ongoing Clinical Studies: > 300 Clinical Studies
• Pharmaceutical Exports Opportunity: > US$ 450 Million by 2025

Biotech pioneers of the Bangladesh Pharmaceutical industry are considered as a valuable tool for the overall improvement and efficacy of the market. To a surprise, Bangladesh pharmaceutical market had been largely dependent on the imports as well as on multinational companies for meeting the needs of the local population. However, in recent times local pharmaceutical companies have emerged as the game changer by contributing more than 90% of the overall available medicines in the market. The pharmaceutical market has been witnessing excellent growth in recent years and is expected to surpass US$ 6 Billion by 2025 with absolute growth of 114% from 2019 levels. Majority of this growth will be contributed by local companies with market share of more than 90% as similar to past trends attained over last two decades.

The notable change that attracted the world towards the country’s market status is the consequence of innovation in science and research and development sector. This has surprisingly transformed the curve of the overall ratio or contribution of Bangladesh pharmaceutical market at the global level. In a short period of time, the breed of biotechnology firm settled in Bangladesh has accumulated certain practices and has qualified itself to bring down the unmet needs and solutions to numerous patient population. Rise in life expectancy, growing per capita income, changing disease profile, population growth, lifestyle changes and growing patient population are some of the key drivers are that are booming the consumption of local market. 

The pioneering impressive export work achieved by the country is the repercussion of the novel biomolecular techniques that have been implemented in the clinical trial platform. The initiatives led by the researchers towards developing a pharmaceutical market have boosted the research and development productivity as well as benefitted the stakeholders and the patients they serve. At present, the total count of the country with respect to clinical trials is more than 300. Bangladesh based pharmaceutical companies have raised their significant amount of clinical trials to advance level. The capital raised by the biotech companies and the research centers has been supported widely by public and private sectors, government bodies and the regulatory bodies. 

Being abundant in pharmaceutical based human resources is formulating the market towards several development programs. Although the country has been competing powerfully with the other emerged markets of the world but digital stringency, which been a transforming source for the other markets is on the move in Bangladesh at a very slow pace. It is important for the Bangladesh pharmaceutical market to interact with dominating markets to improve their platforms for drug discovery and development sector in order to strike with pharmaceutical market of the US and Europe. 

In upcoming years, the government of Bangladesh will play a major role in the rapid growth of pharmaceutical market by providing favorable policies for easy drug approval, production and marketing of new products. Government is focusing to reduce the dependence of Bangladesh over import of raw material and establishment of API Park will act as turning point for this purpose. The top 50 companies are setting their facilities at the active pharmaceuticals ingredient industrial park that will help in production of patented and already opened active pharmaceuticals ingredients. It is expected that the development of API Park will complete by next 2 years, which will reduce the expenditure related to import of raw material.

All the associated factors are in favor for the rapid growth Bangladesh pharmaceutical market and it is expected to grow with a CAGR of more than 12% during 2019-2025 period. The share of generic drugs is expected to surpass 85% by the 2025, which will further strengthen the dominance of local pharmaceutical companies in the market. In addition to this, the presence of leading multinational pharmaceutical companies is also increasing in Bangladesh, which is indicating towards the competitive landscape in upcoming years.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Ocular Hypertension - Pipeline Review, H2 2020

  • $ 2000
  • August 2020
  • 145 pages

Ocular Hypertension - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H2 2020, provides an overview of the Ocula ...


ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on